300791 Stock Overview
Operates as a contract manufacturer for dietary supplement industry worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Sirio Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥27.36 |
| 52 Week High | CN¥35.48 |
| 52 Week Low | CN¥19.32 |
| Beta | 0.90 |
| 11 Month Change | -0.036% |
| 3 Month Change | 14.77% |
| 1 Year Change | 6.24% |
| 33 Year Change | -22.61% |
| 5 Year Change | 38.17% |
| Change since IPO | 37.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300791 | CN Personal Products | CN Market | |
|---|---|---|---|
| 7D | -3.5% | -6.3% | -6.7% |
| 1Y | 6.2% | -15.3% | 1.9% |
Return vs Industry: 300791 exceeded the CN Personal Products industry which returned -15.3% over the past year.
Return vs Market: 300791 exceeded the CN Market which returned 1.9% over the past year.
Price Volatility
| 300791 volatility | |
|---|---|
| 300791 Average Weekly Movement | 8.5% |
| Personal Products Industry Average Movement | 7.5% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.5% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 300791 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300791's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 2,610 | Peiqing Li | www.siriopharma.com |
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutraceutical gummies; probiotic products; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging.
Sirio Pharma Co., Ltd. Fundamentals Summary
| 300791 fundamental statistics | |
|---|---|
| Market cap | CN¥6.41b |
| Earnings (TTM) | CN¥335.69m |
| Revenue (TTM) | CN¥4.13b |
19.1x
P/E Ratio1.6x
P/S RatioIs 300791 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300791 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.13b |
| Cost of Revenue | CN¥2.85b |
| Gross Profit | CN¥1.27b |
| Other Expenses | CN¥938.91m |
| Earnings | CN¥335.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.43 |
| Gross Margin | 30.88% |
| Net Profit Margin | 8.13% |
| Debt/Equity Ratio | 46.1% |
How did 300791 perform over the long term?
See historical performance and comparison